Bioventus Inc.
BVS
$8.97
-$0.18-1.97%
NASDAQ
| 12/31/2025 | 09/27/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 13.88% | -6.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.88% | -6.10% | |||
| Cost of Revenue | 10.57% | -2.52% | |||
| Gross Profit | 15.44% | -7.70% | |||
| SG&A Expenses | 5.23% | -0.57% | |||
| Depreciation & Amortization | -7.22% | -2.85% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.90% | -1.46% | |||
| Operating Income | 92.83% | -38.72% | |||
| Income Before Tax | 202.85% | -54.72% | |||
| Income Tax Expenses | -578.16% | -36.22% | |||
| Earnings from Continuing Operations | 332.30% | -56.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -201.18% | 53.06% | |||
| Net Income | 367.67% | -57.70% | |||
| EBIT | 92.83% | -38.72% | |||
| EBITDA | 19.32% | -25.51% | |||
| EPS Basic | 367.52% | -58.02% | |||
| Normalized Basic EPS | 235.78% | -51.15% | |||
| EPS Diluted | 344.16% | -57.18% | |||
| Normalized Diluted EPS | 234.74% | -51.11% | |||
| Average Basic Shares Outstanding | 0.14% | 0.64% | |||
| Average Diluted Shares Outstanding | 0.62% | 0.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||